Ampco-Pittsburgh (AP) Reports Q1 Loss of $1.00, Revenues Beat
Get Alerts AP Hot Sheet
Financial Fact:
Total operating expenses: 87.8M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Ampco-Pittsburgh (NYSE: AP) reported Q1 EPS of ($1.00), versus $0.12 reported last year. Revenue for the quarter came in at $107.49 million versus the consensus estimate of $95.82 million.
CEO Commentary
Commenting on the quarter’s results, Brett McBrayer, Ampco-Pittsburgh’s Chief Executive Officer said, “The anticipated divestiture of our U.S. cast roll facility and reduction in force action implemented during the quarter are further key steps in the Corporation’s overall restructuring. Excess capacity and high operating costs in our cast roll system have made operation of the Avonmore facility untenable. We expect both actions to improve our operating results from continuing operations by approximately $1.0 million per month on a full run-rate basis, once the sale is complete. Although the Corporation incurred a GAAP loss from continuing operations of $12.0 million in the first quarter, we generated positive non-GAAP adjusted income from continuing operations before the Impairment Charge, the Restructuring-Related Costs and the excess costs of the Avonmore facility. The quarter’s results also reflected an improvement year-over-year as we are beginning to show the benefits of our operational improvement initiatives. These improvements were achieved despite the demand contraction in our frac block business. We are currently engaged in additional asset restructuring opportunities which should facilitate further overhead reduction actions and increase efficiencies in our business. We will continue our restructuring plan with a pace and urgency to fully demonstrate our earnings power.”
For earnings history and earnings-related data on Ampco-Pittsburgh (AP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share